GlassScriptPhysician profile
John T Dvorak
NPI 1902807985
$13,164.97
in general payments reported to CMS, 2019-2025
46 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 79% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,156 · 2020: $977 · 2021: $1,763 · 2022: $2,049 · 2023: $1,615 · 2024: $1,958 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,199 · Education: $21.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,199.05 |
| Education | $21.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,702.75 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,888.95 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,853.02 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,466.41 | 2019-2025 | Tremfya, Stelara, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $782.57 | 2019-2025 | Entyvio, Gattex |
| Davol INC. | $537.57 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $488.22 | 2019-2025 | Rebyota |
| Qol Medical, LLC | $332.48 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $306.68 | 2023-2025 | Omvoh |
| Vioptix INC | $248.02 | 2021 | |
| Janssen Scientific Affairs, LLC | $216.90 | 2022-2024 | |
| Romark Laboratories, Lc | $196.92 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $189.38 | 2023-2025 | Dupixent |
| Genzyme Corporation | $187.93 | 2022-2025 | |
| Celgene Corporation | $176.28 | 2021-2024 | Zeposia |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $165.62 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $159.17 | 2019-2024 | Dificid, Bridion |
| Phathom Pharmaceuticals, INC. | $130.47 | 2023-2025 | Voquezna |
| Amgen INC. | $114.68 | 2020-2022 | |
| Gilead Sciences, INC. | $91.32 | 2024-2025 | |
| Shire North American Group INC | $88.55 | 2019 | |
| Braintree Laboratories, INC. | $85.22 | 2021-2025 | Suflave |
| Evoke Pharma, INC. | $83.82 | 2021-2025 | Gimoti |
| Axonics, INC. | $82.78 | 2020-2024 | Axonics |
| Vivus LLC | $68.08 | 2021-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $62.33 | 2020-2022 | |
| Redhill Biopharma INC. | $51.47 | 2020-2021 | |
| Ethicon US, LLC | $43.04 | 2019-2025 | Echelon Circular |
| Covidien LP | $40.98 | 2020 | |
| Ardelyx, INC. | $37.77 | 2023 | Ibsrela |
| Pacira Pharmaceuticals Incorporated | $30.44 | 2020-2023 | Exparel |
| Ucb, INC. | $29.37 | 2019-2020 | |
| Celltrion USA INC. | $21.29 | 2024 | Zymfentra |
| La Jolla Pharmaceutical Company | $20.56 | 2023 | Xerava |
| Vertex Pharmaceuticals Incorporated | $18.96 | 2024 | |
| Convatec INC. | $18.81 | 2023 | |
| Tela Bio, INC. | $18.49 | 2022 | |
| Shield Therapeutics INC | $18.36 | 2024 | |
| Shionogi INC | $16.71 | 2020 | |
| Daiichi Sankyo INC. | $16.61 | 2022 | |
| Boston Scientific Corporation | $15.27 | 2025 | Axonics |
| Aimmune Therapeutics, INC. | $14.61 | 2025 | Zenpep |
| Acacia Pharma INC | $14.57 | 2021 | |
| Intercept Pharmaceuticals, INC. | $12.03 | 2022 | |
| Thd America, INC. | $11.83 | 2024 | |
| Heron Therapeutics, INC. | $7.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dvorak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.